2019
Frequency of whole-organ in lieu of split-liver transplantation over the last decade: Children experienced increased wait time and death
Valentino PL, Emre S, Geliang G, Li L, Deng Y, Mulligan D, Rodriguez-Davalos M. Frequency of whole-organ in lieu of split-liver transplantation over the last decade: Children experienced increased wait time and death. American Journal Of Transplantation 2019, 19: 3114-3123. PMID: 31152483, DOI: 10.1111/ajt.15481.Peer-Reviewed Original ResearchConceptsAdult recipientsTransplantation Network/United NetworkNumber of allograftsOrgan Sharing dataSplit-liver transplantationCareful patient selectionDeceased donor liversNumber of LTLT graftSLT recipientsUnderwent LTWLT recipientsPediatric candidatesPatient selectionDonor liversOrgan utilizationUnited NetworkOrgan shortageOrgan procurementSmall childrenRecipientsTransplantation
2017
Predictors of Waitlist Mortality in Portopulmonary Hypertension
DuBrock HM, Goldberg DS, Sussman NL, Bartolome SD, Kadry Z, Salgia RJ, Mulligan DC, Kremers WK, Kawut SM, Krowka MJ, Channick RN. Predictors of Waitlist Mortality in Portopulmonary Hypertension. Transplantation 2017, 101: 1609-1615. PMID: 28207639, PMCID: PMC5481480, DOI: 10.1097/tp.0000000000001666.Peer-Reviewed Original ResearchMeSH KeywordsArterial PressureCause of DeathChi-Square DistributionDatabases, FactualDecision Support TechniquesFemaleHumansHypertension, PortalHypertension, PulmonaryKaplan-Meier EstimateLiver DiseasesLiver TransplantationMaleMiddle AgedMultivariate AnalysisPortal PressurePredictive Value of TestsProportional Hazards ModelsPulmonary ArteryPulmonary CirculationRetrospective StudiesRisk AssessmentRisk FactorsSeverity of Illness IndexTime FactorsTissue and Organ ProcurementTreatment OutcomeVascular ResistanceWaiting ListsConceptsPortopulmonary hypertensionWaitlist mortalityMELD exceptionsLiver diseaseException scoreEnd-Stage Liver Disease (MELD) exception pointsSignificant predictorsCox proportional hazards modelMELD exception scoreWaitlist mortality riskRetrospective cohort studyPulmonary arterial pressureTransplantation Network databaseSignificant univariate predictorsOnly significant univariate predictorsProportional hazards modelMELD scorePosttransplant mortalityPulmonary hypertensionCohort studyArterial pressureUnivariate predictorsC-statisticMortality riskHazards model
2013
Genetic Differences in Native Americans and Tacrolimus Dosing After Kidney Transplantation
Chakkera HA, Chang Y, Bodner JK, Behmen S, Heilman RL, Reddy KS, Mulligan DC, Moss AA, Khamash H, Katariya N, Hewitt WR, Pitta TL, Frassetto LA. Genetic Differences in Native Americans and Tacrolimus Dosing After Kidney Transplantation. Transplantation Proceedings 2013, 45: 137-141. PMID: 23375287, DOI: 10.1016/j.transproceed.2012.10.023.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedATP Binding Cassette Transporter, Subfamily BATP Binding Cassette Transporter, Subfamily B, Member 1Cohort StudiesFemaleGenetic VariationHumansImmunosuppressive AgentsIndians, North AmericanKidney Failure, ChronicKidney TransplantationMaleMiddle AgedPharmacogeneticsPolymorphism, Single NucleotideTacrolimusTime FactorsConceptsKidney transplant recipientsTrough levelsTacrolimus dosingTransplant recipientsSingle nucleotide polymorphismsDaily tacrolimus doseLower tacrolimus dosesTacrolimus pharmacokinetic parametersTacrolimus trough levelsCaucasian kidney transplant recipientsStable dosesTacrolimus doseKidney transplantationTacrolimus dosesTacrolimus pharmacokineticsMonths posttransplantationOral clearanceTacrolimus clearanceDrug eliminationPharmacokinetic parametersVariant single nucleotide polymorphismsTacrolimusDrug metabolismPharmacokinetic studyLow dosage
2011
A randomized, multicenter study comparing steroid‐free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C
Klintmalm GB, Davis GL, Teperman L, Netto GJ, Washburn K, Rudich SM, Pomfret EA, Vargas HE, Brown R, Eckhoff D, Pruett TL, Roberts J, Mulligan DC, Charlton MR, Heffron TG, Ham JM, Douglas DD, Sher L, Baliga PK, Kinkhabwala M, Koneru B, Abecassis M, Millis M, Jennings LW, Fasola CG. A randomized, multicenter study comparing steroid‐free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transplantation 2011, 17: 1394-1403. PMID: 21850690, DOI: 10.1002/lt.22417.Peer-Reviewed Original ResearchMeSH KeywordsAdrenal Cortex HormonesAntibodies, Monoclonal, HumanizedAntiviral AgentsBiopsyChi-Square DistributionDaclizumabDrug Therapy, CombinationFemaleGraft RejectionHepacivirusHepatitis C, ChronicHumansImmunoglobulin GImmunosuppressive AgentsKaplan-Meier EstimateLiver FailureLiver TransplantationMaleMiddle AgedMycophenolic AcidProportional Hazards ModelsProspective StudiesRecurrenceRisk AssessmentRisk FactorsRNA, ViralSurvival RateTacrolimusTime FactorsTreatment OutcomeUnited StatesConceptsAcute cellular rejectionSteroid-free immunosuppressionLiver transplant recipientsHCV recurrenceMycophenolate mofetilTransplant recipientsHCV RNA-positive subjectsHepatitis C virus infectionSevere HCV recurrenceSteroid-free groupC virus infectionChronic hepatitis CGraft survival ratesProportion of patientsLiver biopsy samplesCellular rejectionChronic HCVStandard immunosuppressionSteroid sparingHepatitis CLess diabetesMulticenter trialMulticenter studyPatient survivalArm 1
2010
Hepatic epithelioid haemangioendothelioma: is transplantation the only treatment option?
Grotz TE, Nagorney D, Donohue J, Que F, Kendrick M, Farnell M, Harmsen S, Mulligan D, Nguyen J, Rosen C, Reid-Lombardo K. Hepatic epithelioid haemangioendothelioma: is transplantation the only treatment option? Hepato Pancreato Biliary 2010, 12: 546-553. PMID: 20887322, PMCID: PMC2997660, DOI: 10.1111/j.1477-2574.2010.00213.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic AgentsChi-Square DistributionDisease-Free SurvivalFemaleHemangioendothelioma, EpithelioidHepatectomyHumansKaplan-Meier EstimateLiver NeoplasmsLiver TransplantationMaleMiddle AgedPalliative CareProportional Hazards ModelsRetrospective StudiesRisk AssessmentRisk FactorsSurvival RateTime FactorsTreatment OutcomeUnited StatesYoung AdultConceptsHepatic epithelioid haemangioendotheliomaOrthotopic liver transplantationDisease-free survivalLiver resectionOverall survivalPrognostic factorsFavorable prognostic factorUnfavourable prognostic factorOnly treatment optionUnpredictable clinical behaviorRare vascular neoplasmResectable diseaseUnresectable diseaseEpithelioid haemangioendotheliomaLiver transplantationFavorable OSFemale predominanceMedian ageSurgical treatmentMultifocal diseaseRetrospective reviewTreatment optionsLarge tumorsClinical behaviorMayo ClinicEarly Graft Function After Laparoscopically Procured Living Donor Kidney Transplantation
Tyson M, Castle E, Andrews P, Heilman R, Mekeel K, Moss A, Mulligan D, Reddy K. Early Graft Function After Laparoscopically Procured Living Donor Kidney Transplantation. Journal Of Urology 2010, 184: 1434-1439. PMID: 20727548, DOI: 10.1016/j.juro.2010.06.013.Peer-Reviewed Original ResearchConceptsPoor early graft functionEarly graft functionLiving-donor kidney transplantationGraft functionDonor kidney transplantationAcute rejectionKidney transplantationMultivariate logistic regression modelGraft function groupDelayed graft functionDonor kidney transplantsInstitutional review boardLogistic regression modelsAllograft survivalGraft nephrectomyVascular complicationsKidney transplantPerioperative parametersIndependent predictorsTransplantation databaseClinical outcomesPatient survivalBlack ethnicityMale genderDonor ageRelationship between Inpatient Hyperglycemia and Insulin Treatment after Kidney Transplantation and Future New Onset Diabetes Mellitus
Chakkera HA, Knowler WC, Devarapalli Y, Weil EJ, Heilman RL, Dueck A, Mulligan DC, Reddy KS, Moss AA, Mekeel KL, Mazur MJ, Hamawi K, Castro JC, Cook CB. Relationship between Inpatient Hyperglycemia and Insulin Treatment after Kidney Transplantation and Future New Onset Diabetes Mellitus. Clinical Journal Of The American Society Of Nephrology 2010, 5: 1669-1675. PMID: 20558559, PMCID: PMC2974410, DOI: 10.2215/cjn.09481209.Peer-Reviewed Original ResearchConceptsKidney transplant recipientsInpatient hyperglycemiaKidney transplantationTransplant recipientsInsulin therapyNondiabetic kidney transplant recipientsDevelopment of NODATRisk of NODATNew-onset diabetesKidney transplant surgeryCapillary blood glucoseNondiabetic patientsYear posttransplantCardiovascular eventsNew onsetDiabetes mellitusMedical therapyAdjusted analysisStudy cohortRetrospective studyTransplant surgeryBlood glucoseSerum glucoseInsulin treatmentNODAT
2009
Natural history of post–liver transplantation hepatitis C: A review of factors that may influence its course
Gallegos‐Orozco J, Yosephy A, Noble B, Aqel BA, Byrne TJ, Carey EJ, Douglas DD, Mulligan D, Moss A, de Petris G, Williams JW, Rakela J, Vargas HE. Natural history of post–liver transplantation hepatitis C: A review of factors that may influence its course. Liver Transplantation 2009, 15: 1872-1881. PMID: 19938138, DOI: 10.1002/lt.21954.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdultBiopsyDisease ProgressionFemaleGraft RejectionHepatitis CHumansKaplan-Meier EstimateLiver CirrhosisLiver FailureLiver TransplantationLiving DonorsMaleMiddle AgedProportional Hazards ModelsRecurrenceRetrospective StudiesRisk AssessmentRisk FactorsSeverity of Illness IndexTime FactorsTreatment OutcomeConceptsEnd-stage liver diseaseHCV-positive recipientsLiver transplantHepatocellular carcinomaHCV recurrenceAcute rejectionPatient survivalBiopsy-proven acute rejectionMedian age 53 yearsHistory of HCCAggressive HCV recurrenceEarly acute rejectionProtocol liver biopsiesSignificant HCV recurrenceAdult liver transplantsAdvanced donor ageAge 53 yearsAge 39 yearsDay of transplantationLong-term survivalElectronic medical recordsAvoidance of rejectionEvaluable populationRapid fibrosersHepatitis CHyperglycemia during the Immediate Period after Kidney Transplantation
Chakkera HA, Weil EJ, Castro J, Heilman RL, Reddy KS, Mazur MJ, Hamawi K, Mulligan DC, Moss AA, Mekeel KL, Cosio FG, Cook CB. Hyperglycemia during the Immediate Period after Kidney Transplantation. Clinical Journal Of The American Society Of Nephrology 2009, 4: 853-859. PMID: 19339426, PMCID: PMC2666437, DOI: 10.2215/cjn.05471008.Peer-Reviewed Original ResearchConceptsNew-onset diabetesKidney transplantationPretransplantation diabetesHospital dischargeImmediate posttransplantation periodPrevalence of hypoglycemiaKidney transplant recipientsStress of surgeryShort-acting insulinEvidence of hyperglycemiaHospital stayImmunosuppression medicationsPharmacologic managementTransplant recipientsHospital phasePosttransplantation periodPharmacy databaseStudy cohortProspective studyTransient hyperglycemiaObservational studyMetabolic effectsHyperglycemiaPatientsTransplantationOutcomes of Simultaneous Kidney–Pancreas Transplantation With Positive Cross-Match
Heilman R, Chakkera H, Mazur M, Petrides S, Moss A, Mekeel K, Mulligan D, Reddy K. Outcomes of Simultaneous Kidney–Pancreas Transplantation With Positive Cross-Match. Transplantation Proceedings 2009, 41: 303-306. PMID: 19249540, DOI: 10.1016/j.transproceed.2008.08.154.Peer-Reviewed Original ResearchMeSH KeywordsAlemtuzumabAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntibodies, NeoplasmAntilymphocyte SerumDrug Therapy, CombinationFollow-Up StudiesGraft SurvivalHistocompatibility TestingHumansImmunoglobulins, IntravenousImmunosuppressive AgentsKidney TransplantationPancreas TransplantationRetrospective StudiesSurvival AnalysisTime FactorsTreatment OutcomeConceptsAntibody-mediated rejectionLow-dose intravenous immunoglobulinAcute cellular rejectionIntravenous immunoglobulinStudy groupControl groupAllograft survivalMycophenolate mofetilRisk of AMRSimultaneous pancreas-kidney transplant recipientsPancreas-kidney transplant recipientsSimultaneous kidney-pancreas transplantationDose intravenous immunoglobulinKidney-pancreas transplantationPositive cross matchRabbit antithymocyte globulinActuarial patient survivalKidney allograft survivalKidney transplant recipientsPancreas allograft survivalAcute rejectionAntithymocyte globulinCellular rejectionSPKT recipientsKidney allografts
2006
Reduced Priority MELD Score for Hepatocellular Carcinoma Does Not Adversely Impact Candidate Survival Awaiting Liver Transplantation
Sharma P, Harper AM, Hernandez JL, Heffron T, Mulligan DC, Wiesner RH, Balan V. Reduced Priority MELD Score for Hepatocellular Carcinoma Does Not Adversely Impact Candidate Survival Awaiting Liver Transplantation. American Journal Of Transplantation 2006, 6: 1957-1962. PMID: 16771808, DOI: 10.1111/j.1600-6143.2006.01411.x.Peer-Reviewed Original ResearchConceptsDeceased donor liver transplantationHepatocellular carcinomaHCC candidatesCandidate survivalLiver transplantationMELD scoreStage T1Waiting listEnd-stage liver diseaseDonor liver transplantationT2 hepatocellular carcinomaOrgan allocation policyUNOS databaseLiver transplantLiver diseasePatient survivalUnited NetworkHCC patientsIncidence rateOrgan SharingSurvivalTransplantationCarcinomaDropout rateTime periodLiving donor liver transplantation for hepatitis C‐related cirrhosis: No difference in histological recurrence when compared to deceased donor liver transplantation recipients
Guo L, Orrego M, Rodriguez‐Luna H, Balan V, Byrne T, Chopra K, Douglas DD, Harrison E, Moss A, Reddy KS, Williams JW, Rakela J, Mulligan D, Vargas HE. Living donor liver transplantation for hepatitis C‐related cirrhosis: No difference in histological recurrence when compared to deceased donor liver transplantation recipients. Liver Transplantation 2006, 12: 560-565. PMID: 16555313, DOI: 10.1002/lt.20660.Peer-Reviewed Original ResearchConceptsDeceased donor liver transplantationDonor liver transplantationLiver transplantationHistological recurrenceHepatitis CDeceased-donor liver transplantation (DDLT) recipientsEnd-stage liver disease (MELD) scoreDonor liver transplantation recipientsHepatitis C virus infectionKaplan-Meier survival analysisDetectable HCV RNAHistological recurrence rateC virus infectionGraft survival ratesLiver Disease scoreActivity of inflammationLiver transplantation recipientsStatistical differenceChild-TurcotteDDLT groupLDLT patientsPugh scoreRecurrent HCVLiver transplantYears posttransplantation
2005
Regional Variations in Peer Reviewed Liver Allocation Under the MELD System
Rodriguez‐Luna H, Vargas HE, Moss A, Reddy KS, Freeman RB, Mulligan D. Regional Variations in Peer Reviewed Liver Allocation Under the MELD System. American Journal Of Transplantation 2005, 5: 2244-2247. PMID: 16095504, DOI: 10.1111/j.1600-6143.2005.01008.x.Peer-Reviewed Original Research
2004
Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon &agr;2b and ribavirin: an open-label series1
Rodriguez-Luna H, Khatib A, Sharma P, De Petris G, Williams JW, Ortiz J, Hansen K, Mulligan D, Moss A, Douglas DD, Balan V, Rakela J, Vargas HE. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon &agr;2b and ribavirin: an open-label series1. Transplantation 2004, 77: 190-194. PMID: 14742979, DOI: 10.1097/01.tp.0000100481.14514.bb.Peer-Reviewed Original ResearchMeSH KeywordsAntiviral AgentsDrug Therapy, CombinationFemaleHepacivirusHepatitis CHumansImmunosuppressive AgentsInterferon alpha-2Interferon-alphaLiver Function TestsLiver TransplantationMaleMiddle AgedPolyethylene GlycolsRecombinant ProteinsRecurrenceReverse Transcriptase Polymerase Chain ReactionRibavirinRNA, ViralTime FactorsTreatment OutcomeConceptsOrthotopic liver transplantationEnd of treatmentHCV recurrenceLiver transplantationPEG-IFNHepatitis C virus recurrenceRecurrent hepatitis C infectionDiscontinuation of therapyNecro-inflammatory scoreUndetectable viral loadHepatitis C infectionResponse 6 monthsBone marrow toxicityReverse transcriptase-polymerase chain reactionTranscriptase-polymerase chain reactionHistologic benefitRecurrent HCVVirologic clearanceC infectionVirologic responseVirus recurrenceAggressive managementCombination regimenViral clearanceViral response
1997
Intrathymic spleen cell inoculation and ALS fails to induce tolerance to rat pancreas allografts
Schulak JA, Mulligan DC, Robinson A. Intrathymic spleen cell inoculation and ALS fails to induce tolerance to rat pancreas allografts. Transplantation Proceedings 1997, 29: 1070-1071. PMID: 9123203, DOI: 10.1016/s0041-1345(96)00405-8.Peer-Reviewed Original ResearchAnimalsAntilymphocyte SerumGraft SurvivalHeart TransplantationHistocompatibility Antigens Class IHistocompatibility Antigens Class IIImmunosuppression TherapyLymphocyte TransfusionMajor Histocompatibility ComplexMalePancreas TransplantationRatsRats, Inbred BUFRats, Inbred LewSpleenThymus GlandTime FactorsTransplantation, HomologousReduction of early rejection in adult liver transplantation with ATG induction therapy
Schulak J, May E, Post A, Fasola C, Mulligan D, Sterling R. Reduction of early rejection in adult liver transplantation with ATG induction therapy. Transplantation Proceedings 1997, 29: 555-556. PMID: 9123126, DOI: 10.1016/s0041-1345(96)00264-3.Peer-Reviewed Original Research
1995
QUALITY OF LIFE IMPROVEMENTS AT ONE, TWO, AND FIVE YEARS AFTER LIVER TRANSPLANTATION1,2
Levy M, Jennings L, Abouljoud M, Mulligan D, Goldstein R, Husberg B, Gonwa T, Klintmalm G. QUALITY OF LIFE IMPROVEMENTS AT ONE, TWO, AND FIVE YEARS AFTER LIVER TRANSPLANTATION1,2. Transplantation 1995, 59: 515-518. PMID: 7878756, DOI: 10.1097/00007890-199502270-00013.Peer-Reviewed Original ResearchConceptsQuality of lifeHealth perceptionPosttransplant yearAdult liver transplant recipientsBetter QOLPosttransplant time pointsFirst posttransplant yearLiver transplant recipientsTransplant recipientsAdult patientsOLTxSymptom frequencyYear postDaily livingImpact of healthHealth statusTime pointsPsychological questionnairesHealth interferencePatientsScoresHealth limitationsYearsUse of anti-hepatitis C virus seropositive organs in liver transplantation.
Mulligan DC, Goldstein RM, Crippin JS, Abouljoud MS, Levy MF, Husberg BS, Gonwa TA, Foster BR, Tillery GW, Klintmalm GB. Use of anti-hepatitis C virus seropositive organs in liver transplantation. Transplantation Proceedings 1995, 27: 1204-5. PMID: 7878850.Peer-Reviewed Original ResearchA Comparison Of Treatment With Transjugular Intrahepatic Portosystemic Shunt Or Distal Splenorenal Shunt In The Management Of Variceal Bleeding Prior To Liver Transplantation
Abouljoud M, Levy M, Rees C, Diamond N, Lee S, Mulligan D, Goldstein R, Husberg B, Gonwa T, Klintmalm G. A Comparison Of Treatment With Transjugular Intrahepatic Portosystemic Shunt Or Distal Splenorenal Shunt In The Management Of Variceal Bleeding Prior To Liver Transplantation. Transplantation 1995, 59: 226-229. PMID: 7839445, DOI: 10.1097/00007890-199501270-00013.Peer-Reviewed Original ResearchConceptsTransjugular intrahepatic portosystemic shuntDistal splenorenal shuntIntrahepatic portosystemic shuntDSRS groupVariceal bleedingLiver transplantationSurgical shuntsSplenorenal shuntLiver diseasePortosystemic shuntTIPS groupRole of TIPSPrevious transjugular intrahepatic portosystemic shuntEnd-stage liver diseaseChild-Pugh C patientsIntraoperative hemodynamic measurementsSubsequent transplant procedureAdvanced liver diseaseLiver transplant candidatesLiver transplant recipientsRecurrent variceal bleedingGroup of patientsFirst-line managementBlood flow measurementsComparison of treatments